| Subject |
Date
(D/M/Y) |
| This link will open in a new windowOlanzapine: Assessing the potential risks of syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia (Letter to Healthcare Professionals) |
1-11-2024 |
| This link will open in a new windowGavreto® (pralsetinib): New warning and precaution of severe and fatal infections (Letter to Healthcare Professionals) |
30-10-2024 |
| This link will open in a new windowVigilance against Hand, Foot and Mouth Disease |
9-10-2024 |
| This link will open in a new windowVigilance Against Dengue Fever During And After Holidays |
2-10-2024 |
| This link will open in a new windowSummary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals) |
27-9-2024 |
| This link will open in a new windowPlaquenil® (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms (Letter to Healthcare Professionals) |
20-9-2024 |
| This link will open in a new windowVigilance against Invasive Group B Streptococcus Infection |
14-9-2024 |
| This link will open in a new windowLunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis (Letter to Healthcare Professionals) |
13-9-2024 |
| This link will open in a new windowEMA recommends measures to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate (Letter to Healthcare Professionals) |
9-9-2024 |
| This link will open in a new windowA locally acquired case of dengue fever |
17-8-2024 |
| This link will open in a new windowWHO declared mpox outbreak as a Public Health Emergency of International Concern |
15-8-2024 |
| This link will open in a new windowAzithromycin and rare risk of cardiovascular death (Letter to Healthcare Professionals) |
2-8-2024 |
| This link will open in a new windowEMA advises about risks of using weight loss medicine Mysimba with opioids (Letter to Healthcare Professionals) |
29-7-2024 |
| This link will open in a new windowThematic Report on Iron Status (Population Health Survey 2020-22) |
16-7-2024 |
| This link will open in a new windowNew recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation (Letter to Healthcare Professionals) |
15-7-2024 |
| This link will open in a new windowNexavar (sorafenib): Assessing the potential risk of tumour lysis syndrome (Letter to Healthcare Professionals) |
28-6-2024 |
| This link will open in a new windowWarfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals) |
21-6-2024 |
| This link will open in a new windowA probably locally acquired case of dengue fever in 2024 |
19-6-2024 |
| This link will open in a new windowCAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals) |
17-6-2024 |
| This link will open in a new windowVigilance against upsurge of pertussis |
24-5-2024 |
| This link will open in a new windowUpdate on increased Seasonal Influenza Activity in Hong Kong |
2-5-2024 |
| This link will open in a new windowCHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals) |
29-4-2024 |
| This link will open in a new windowThe first local case of dengue fever in 2024 |
26-4-2024 |
| This link will open in a new windowVigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” |
5-4-2024 |
| This link will open in a new windowEzetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowAmiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowIbrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowUpdated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) |
21-3-2024 |
| This link will open in a new windowColistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals) |
1-3-2024 |
| This link will open in a new windowVigilance against upsurge of measles |
29-2-2024 |
| This link will open in a new windowVigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection |
30-1-2024 |
| This link will open in a new windowSafety-related information for the product Mifegyne (Letter to Healthcare Professionals) |
25-1-2024 |
| This link will open in a new window含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals) (Chinese only) |
24-1-2024 |
| This link will open in a new windowBCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) |
24-1-2024 |
| This link will open in a new windowFluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) |
23-1-2024 |
| This link will open in a new windowArrival of the 2023/24 Winter Influenza Season in Hong Kong |
11-1-2024 |